

Bill H Diplas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2035333/publications.pdf>

Version: 2024-02-01

28
papers

2,668
citations

361413

20
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

5276
citing authors

#	ARTICLE	IF	CITATIONS
1	TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. <i>Nature Genetics</i> , 2011, 43, 189-196.	21.4	326
2	Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. <i>Nature Genetics</i> , 2010, 42, 619-625.	21.4	261
3	Mutations in <i>IDH1</i> , <i>IDH2</i> , and in the <i>TERT</i> promoter define clinically distinct subgroups of adult malignant gliomas. <i>Oncotarget</i> , 2014, 5, 1515-1525.	1.8	237
4	Biological Role and Therapeutic Potential of IDH Mutations in Cancer. <i>Cancer Cell</i> , 2018, 34, 186-195.	16.8	234
5	Isocitrate dehydrogenase mutations in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 16-26.	1.2	221
6	Missense Mutations in TCF8 Cause Late-Onset Fuchs Corneal Dystrophy and Interact with FCD4 on Chromosome 9p. <i>American Journal of Human Genetics</i> , 2010, 86, 45-53.	6.2	167
7	Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. <i>European Journal of Cancer</i> , 2015, 51, 969-976.	2.8	150
8	The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. <i>New England Journal of Medicine</i> , 2021, 384, 1168-1170.	27.0	137
9	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 223-229.	8.2	130
10	Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6308-6312.	7.1	127
11	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. <i>Nature Communications</i> , 2018, 9, 2087.	12.8	124
12	Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. <i>Acta Neuropathologica</i> , 2019, 137, 297-306.	7.7	109
13	Evolutionarily Assembled cis-Regulatory Module at a Human Ciliopathy Locus. <i>Science</i> , 2012, 335, 966-969.	12.6	84
14	Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. <i>Journal of Pathology</i> , 2016, 239, 72-83.	4.5	56
15	Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of <i>ATR</i> -Mutant Cancers to WEE1 Inhibition. <i>Cancer Research</i> , 2020, 80, 510-523.	0.9	52
16	The integrated genomic and epigenomic landscape of brainstem glioma. <i>Nature Communications</i> , 2020, 11, 3077.	12.8	50
17	<i>Cic</i> Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation. <i>Cancer Research</i> , 2017, 77, 6097-6108.	0.9	46
18	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. <i>Cancer Research</i> , 2018, 78, 36-50.	0.9	35

#	ARTICLE	IF	CITATIONS
19	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28
20	Sensitive and rapid detection of <i>TERT</i> promoter and <i>IDH</i> mutations in diffuse gliomas. <i>Neuro-Oncology</i> , 2019, 21, 440-450.	1.2	27
21	Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. <i>Molecular Cancer Research</i> , 2020, 18, 968-980.	3.4	18
22	CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. <i>Molecular Cancer Research</i> , 2019, 17, 2042-2050.	3.4	15
23	Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
24	SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. <i>Modern Pathology</i> , 2021, 34, 1810-1819.	5.5	8
25	TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. <i>Acta Neuropathologica Communications</i> , 2021, 9, 178.	5.2	8
26	Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells. <i>Scientific Reports</i> , 2018, 8, 12507.	3.3	5
27	The Role of Ablative Radiotherapy in Older Adults With Limited Metastatic Disease. <i>Seminars in Radiation Oncology</i> , 2022, 32, 135-141.	2.2	2
28	GENE-01. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi102-vi103.	1.2	0